A Designed Inhibitor of p53 Aggregation Rescues p53 Tumor Suppression in Ovarian Carcinomas

Cancer Cell

Volumn 29, Issue 1, 2016, Pages 90-103

  Soragni, Alice ^a   Janzen, Deanna M ^b   Johnson, Lisa M ^a   Lindgren, Anne G ^b   Thai Quynh Nguyen, Anh ^a,f   Tiourin, Ekaterina ^b   Soriaga, Angela B ^a   Lu, Jing ^c   Jiang, Lin ^a,b   Faull, Kym F ^d   Pellegrini, Matteo ^c   Memarzadeh, Sanaz ^b,c,e   Eisenberg, David S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^f UNIVERSITY OF NATURAL SCIENCES   (Viet Nam)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID; CELL PENETRATING PEPTIDE; PROTEIN P53;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL LINE; CANCER INHIBITION; CELL CYCLE ARREST; CELL DEATH; CELL PROLIFERATION; CONTROLLED STUDY; CYTOPLASM; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN FUNCTION; TUMOR GROWTH; TUMOR XENOGRAFT; ANIMAL; CELL CULTURE; CELL LINE; DISEASE MODEL; FEMALE; GENETICS; METABOLISM; OVARY TUMOR; PATHOLOGY; TRANSGENIC MOUSE;

ANIMALS; CELL LINE; CELL PROLIFERATION; CELLS, CULTURED; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; MICE, TRANSGENIC; OVARIAN NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84957910884     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccell.2015.12.002     Document Type: Article

References (56)

1. Ahmed A.A., Etemadmoghadam D., Temple J., Lynch A.G., Riad M., Sharma R., Stewart C., Fereday S., Caldas C., Defazio A., et al. Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. J. Pathol. 2010, 221:49-56.
2. Anderson L., Hunter C.L. Quantitative mass spectrometric multiple reaction monitoring assays for major plasma proteins. Mol. Cell Proteomics 2006, 5:573-588.
3. Bullock A.N., Fersht A.R. Rescuing the function of mutant p53. Nat. Rev. Cancer 2001, 1:68-76.
4. Bullock A.N., Henckel J., DeDecker B.S., Johnson C.M., Nikolova P.V., Proctor M.R., Lane D.P., Fersht A.R. Thermodynamic stability of wild-type and mutant p53 core domain. Proc. Natl. Acad. Sci. USA 1997, 94:14338-14342.
5. Bykov V.J.N., Issaeva N., Shilov A., Hultcrantz M., Pugacheva E., Chumakov P., Bergman J., Wiman K.G., Selivanova G. Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat. Med. 2002, 8:282-288.
6. Cancer Genome Atlas Research Network Integrated genomic analyses of ovarian carcinoma. Nature 2011, 474:609-615.
7. Chen C.L., Ip S.M., Cheng D., Wong L.C., Ngan H.Y. P73 gene expression in ovarian cancer tissues and cell lines. Clin. Cancer Res. 2000, 6:3910-3915.
8. Eisenberg D., Jucker M. The amyloid state of proteins in human diseases. Cell 2012, 148:1188-1203.
9. Freed-Pastor W.A., Mizuno H., Zhao X., Langerød A., Moon S.-H., Rodriguez-Barrueco R., Barsotti A., Chicas A., Li W., Polotskaia A., et al. Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway. Cell 2012, 148:244-258.
10. Fuchs S.M., Raines R.T. Polyarginine as a multifunctional fusion tag. Protein Sci. 2005, 14:1538-1544.
11. Ghosh S., Ghosh D., Ranganathan S., Anoop A., P S.K., Jha N.N., Padinhateeri R., Maji S.K. Investigating the intrinsic aggregation potential of evolutionarily conserved segments in p53. Biochemistry 2014, 53:5995-6010.
12. Goldschmidt L., Teng P.K., Riek R., Eisenberg D. Identifying the amylome, proteins capable of forming amyloid-like fibrils. Proc. Natl. Acad. Sci. USA 2010, 107:3487-3492.
13. Härd T., Lendel C. Inhibition of amyloid formation. J. Mol. Biol. 2012, 421:441-465.
14. Hashimoto K., Morishige K., Sawada K., Tahara M., Kawagishi R., Ikebuchi Y., Sakata M., Tasaka K., Murata Y. Alendronate inhibits intraperitoneal dissemination in in vivo ovarian cancer model. Cancer Res. 2005, 65:540-545.
15. Issaeva N., Friedler A., Bozko P., Wiman K.G., Fersht A.R., Selivanova G. Rescue of mutants of the tumor suppressor p53 in cancer cells by a designed peptide. Proc. Natl. Acad. Sci. USA 2003, 100:13303-13307.
16. Janzen D.M., Tiourin E., Salehi J.A., Paik D.Y., Lu J., Pellegrini M., Memarzadeh S. An apoptosis-enhancing drug overcomes platinum resistance in a tumour-initiating subpopulation of ovarian cancer. Nat. Commun. 2015, 6:7956.
17. Joerger A.C., Fersht A.R. Structural biology of the tumor suppressor p53. Annu. Rev. Biochem. 2008, 77:557-582.
18. Khoo K.H., Verma C.S., Lane D.P. Drugging the p53 pathway: understanding the route to clinical efficacy. Nat. Rev. Drug Discov. 2014, 13:217-236.
19. Knight L.A., Kurbacher C.M., Glaysher S., Fernando A., Reichelt R., Dexel S., Reinhold U., Cree I.A. Activity of mevalonate pathway inhibitors against breast and ovarian cancers in the ATP-based tumour chemosensitivity assay. BMC Cancer 2009, 9:38.
20. Kruiswijk F., Labuschagne C.F., Vousden K.H. p53 in survival, death and metabolic health: a lifeguard with a licence to kill. Nat. Rev. Mol. Cell Biol. 2015, 16:393-405.
21. Kurman R.J., Shih I.-M. Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications. Int. J. Gynecol. Pathol. 2008, 27:151-160.
22. Lane D.P., Crawford L.V. T antigen is bound to a host protein in SY40-transformed cells. Nature 1979, 278:261-263.
23. Lasagna-Reeves C.A., Clos A.L., Castillo-Carranza D., Sengupta U., Guerrero-Muñoz M., Kelly B., Wagner R., Kayed R. Dual role of p53 amyloid formation in cancer; loss of function and gain of toxicity. Biochem. Biophys. Res. Commun. 2013, 430:963-968.
24. Leaver-Fay A., Tyka M., Lewis S.M., Lange O.F., Thompson J., Jacak R., Kaufman K., Renfrew P.D., Smith C.A., Sheffler W., et al. ROSETTA3: an object-oriented software suite for the simulation and design of macromolecules. Methods Enzymol. 2011, 487:545-574.
25. Lehmann S., Bykov V.J.N., Ali D., Andrén O., Cherif H., Tidefelt U., Uggla B., Yachnin J., Juliusson G., Moshfegh A., et al. Targeting p53 in vivo: a first-in-human study with p53-targeting compound APR-246 in refractory hematologic malignancies and prostate cancer. J. Clin. Oncol. 2012, 30:3633-3639.
26. Leitao M.M., Soslow R.A., Baergen R.N., Olvera N., Arroyo C., Boyd J. Mutation and expression of the TP53 gene in early stage epithelial ovarian carcinoma. Gynecol. Oncol. 2004, 93:301-306.
27. L'Espérance S., Bachvarova M., Tetu B., Mes-Masson A.-M., Bachvarov D. Global gene expression analysis of early response to chemotherapy treatment in ovarian cancer spheroids. BMC Genomics 2008, 9:99.
28. Levine A.J., Oren M. The first 30 years of p53: growing ever more complex. Nat. Rev. Cancer 2009, 9:749-758.
29. Levy C.B., Stumbo A.C., Ano Bom A.P.D., Portari E.A., Cordeiro Y., Carneiro Y., Silva J.L., De Moura-Gallo C.V. Co-localization of mutant p53 and amyloid-like protein aggregates in breast tumors. Int. J. Biochem. Cell Biol. 2011, 43:60-64.
30. Linzer D.I.H., Levine A.J. Characterization of a 54K Dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells. Cell 1979, 17:43-52.
31. Liu X., Wilcken R., Joerger A.C., Chuckowree I.S., Amin J., Spencer J., Fersht A.R. Small molecule induced reactivation of mutant p53 in cancer cells. Nucleic Acids Res. 2013, 41:6034-6044.
32. Martirosyan A., Clendening J.W., Goard C.A., Penn L.Z. Lovastatin induces apoptosis of ovarian cancer cells and synergizes with doxorubicin: potential therapeutic relevance. BMC Cancer 2010, 10:103.
33. Morgan R.J., Alvarez R.D., Armstrong D.K., Burger R.A., Chen L., Copeland L., Crispens M.A., Gershenson D.M., Gray H.J., Hakam A., et al. Ovarian cancer, version 2.2013. J. Natl. Compr. Canc Netw. 2013, 11:1199-1209.
34. Muller P.A.J., Vousden K.H. p53 mutations in cancer. Nat. Cell Biol. 2013, 15:2-8.
35. Naora H., Montell D.J. Ovarian cancer metastasis: integrating insights from disparate model organisms. Nat. Rev. Cancer 2005, 5:355-366.
36. Petitjean A., Mathe E., Kato S., Ishioka C., Tavtigian S.V., Hainaut P., Olivier M. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum. Mutat. 2007, 28:622-629.
37. Rieber M., Strasberg-Rieber M. Hypoxia, Mn-SOD and H(2)O(2) regulate p53 reactivation and PRIMA-1 toxicity irrespective of p53 status in human breast cancer cells. Biochem. Pharmacol. 2012, 84:1563-1570.
38. Rufini A., Agostini M., Grespi F., Tomasini R., Sayan B.S., Niklison-Chirou M.V., Conforti F., Velletri T., Mastino A., Mak T.W., et al. p73 in cancer. Genes Cancer 2011, 2:491-502.
39. Sawaya M.R., Sambashivan S., Nelson R., Ivanova M.I., Sievers S.A., Apostol M.I., Thompson M.J., Balbirnie M., Wiltzius J.J.W., McFarlane H.T., et al. Atomic structures of amyloid cross-beta spines reveal varied steric zippers. Nature 2007, 447:453-457.
40. Seidman J.D., Horkayne-Szakaly I., Haiba M., Boice C.R., Kurman R.J., Ronnett B.M. The histologic type and stage distribution of ovarian carcinomas of surface epithelial origin. Int. J. Gynecol. Pathol. 2004, 23:41-44.
41. Siddik Z.H. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 2003, 22:7265-7279.
42. Siegel R., Ma J., Zou Z., Jemal A. Cancer statistics, 2014. CA Cancer J. Clin. 2014, 64:9-29.
43. Sievers S.A., Karanicolas J., Chang H.W., Zhao A., Jiang L., Zirafi O., Stevens J.T., Münch J., Baker D., Eisenberg D. Structure-based design of non-natural amino-acid inhibitors of amyloid fibril formation. Nature 2011, 475:96-100.
44. Silva J.L., Gallo C.V.D.M., Costa D.C.F., Rangel L.P. Prion-like aggregation of mutant p53 in cancer. Trends Biochem. Sci. 2014, 39:260-267.
45. Tophkhane C., Yang S.-H., Jiang Y., Ma Z., Subramaniam D., Anant S., Yogosawa S., Sakai T., Liu W.-G., Edgerton S., et al. p53 inactivation upregulates p73 expression through E2F-1 mediated transcription. PLoS One 2012, 7:e43564.
46. Vassilev L.T., Vu B.T., Graves B., Carvajal D., Podlaski F., Filipovic Z., Kong N., Kammlott U., Lukacs C., Klein C., et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004, 303:844-848.
47. Vaughan S., Coward J.I., Bast R.C., Berchuck A., Berek J.S., Brenton J.D., Coukos G., Crum C.C., Drapkin R., Etemadmoghadam D., et al. Rethinking ovarian cancer: recommendations for improving outcomes. Nat. Rev. Cancer 2011, 11:719-725.
48. Vaughan C.A., Frum R., Pearsall I., Singh S., Windle B., Yeudall A., Deb S.P., Deb S. Allele specific gain-of-function activity of p53 mutants in lung cancer cells. Biochem. Biophys. Res. Commun. 2012, 428:6-10.
49. Vazquez A., Bond E.E., Levine A.J., Bond G.L. The genetics of the p53 pathway, apoptosis and cancer therapy. Nat. Rev. Drug Discov. 2008, 7:979-987.
50. Ventura A., Kirsch D.G., McLaughlin M.E., Tuveson D.A., Grimm J., Lintault L., Newman J., Reczek E.E., Weissleder R., Jacks T. Restoration of p53 function leads to tumour regression in vivo. Nature 2007, 445:661-665.
51. Vossio S., Palescandolo E., Pediconi N., Moretti F., Balsano C., Levrero M., Costanzo A. DN-p73 is activated after DNA damage in a p53-dependent manner to regulate p53-induced cell cycle arrest. Oncogene 2002, 21:3796-3803.
52. Vousden K.H., Ryan K.M. p53 and metabolism. Nat. Rev. Cancer 2009, 9:691-700.
53. Wang G., Fersht A.R. First-order rate-determining aggregation mechanism of p53 and its implications. Proc. Natl. Acad. Sci. USA 2012, 109:13590-13595.
54. Wilcken R., Wang G., Boeckler F.M., Fersht A.R. Kinetic mechanism of p53 oncogenic mutant aggregation and its inhibition. Proc. Natl. Acad. Sci. USA 2012, 109:13584-13589.
55. Xu J., Reumers J., Couceiro J.R., De Smet F., Gallardo R., Rudyak S., Cornelis A., Rozenski J., Zwolinska A., Marine J.-C., et al. Gain of function of mutant p53 by coaggregation with multiple tumor suppressors. Nat. Chem. Biol. 2011, 7:285-295.
56. Yu X., Vazquez A., Levine A.J., Carpizo D.R. Allele specific p53 mutant reactivation. Cancer Cell 2012, 21:614-625.